Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301039 · ClinicalTrials.gov registry record · Phase 2
SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
A Phase 2 study of Soft Tissue Sarcoma and Bone Sarcoma, sponsored by Sarcoma Alliance for Research through Collaboration.
- Completed
- Registry status
- Phase 2
- Development phase
- 144
- Enrollment target
- 12
- Study locations
NCT02301039: Completed Phase 2 study of Soft Tissue Sarcoma and Bone Sarcoma, sponsored by Sarcoma Alliance for Research through Collaboration.
NCT02301039 is a Phase 2 study of Soft Tissue Sarcoma and Bone Sarcoma that has completed, run by Sarcoma Alliance for Research through Collaboration. The registered enrollment target is 144 participants, above the 76-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (89% higher). The trial reports 12 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02301039, a Phase 2 study of Soft Tissue Sarcoma and Bone Sarcoma, has completed, sponsored by Sarcoma Alliance for Research through Collaboration.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 144 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
Primary Outcome
The Objective Response Rate (ORR) is the percentage of patient's tumor that shrinks or disappears after treatment. ORR will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1, whereby Complete Response is defined as the disappearance of all target lesions and Partial Response is defined as at least a 30% decrease in the sum of the diameters of target lesions in reference to the baseline diameters. Overall Response (OR) = CR + PR.
Conditions Studied
Interventions
- DRUG Pembrolizumab
Study Locations (12)
Florida
- Mayo Clinic Florida - Jacksonville
- H. Lee Moffitt Cancer Center - Tampa
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
- UPMC Hillman Cancer Center - Pittsburgh
California
- University of Southern California - Los Angeles
District of Columbia
- Medstar Health Research Institute - Washington D.C.
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic Cancer Center - Rochester
Missouri
- Washington University in St. Louis - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2015-03 |
| Est. Completion | 2020-07-01 |
| Phase | Phase 2 |
What the finished NCT02301039 record still lists
NCT02301039 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, above the 76-participant average among 55 other Soft Tissue Sarcoma trials with a reported enrollment target (89% higher).
The record links to 2 conditions, with Soft Tissue Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02301039 lists 12 locations in 10 states (Florida, Pennsylvania, California).
Frequently Asked Questions
What is clinical trial NCT02301039 about?
NCT02301039 is a clinical study titled "SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas". The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas.
What is the current status of trial NCT02301039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 144 participants. The study started on 2015-03. Estimated completion is 2020-07-01.
What conditions does trial NCT02301039 study?
This clinical trial studies the following conditions: Soft Tissue Sarcoma, Bone Sarcoma.
What interventions are being tested in trial NCT02301039?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02301039?
This trial is sponsored by Sarcoma Alliance for Research through Collaboration, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02301039 being conducted?
This trial has 12 study locations across California, District of Columbia, Florida, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Soft Tissue Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02301039's enrollment target sits among peer trials
144 9th of 55 higher than 47 of 55 other Soft Tissue Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Soft Tissue Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Investigate the Efficacy of Intratumoral Tigilanol Tiglate in Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
RECRUITING · Phase 2
-
SATURN-STS: Phase II Study of Neoadjuvant Atezolizumab With Doxorubicin, Concurrent Atezolizumab With Pre-operative Radiation Therapy and Adjuvant Atezolizumab in Patients With High-risk Surgically Resectable Extremity and Truncal Soft Tissue Sarcoma
RECRUITING · Phase 2
-
5-Day Preoperative Radiation for Soft Tissue Sarcoma
RECRUITING · Phase 2
-
Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia